Protalix Biotherapeutics Inc., of Carmiel, Israel, reported results from a phase II trial testing OPRX-106, recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain, in 24 patients with active mild to moderate ulcerative colitis.